Four businesspeople sitting around a table in a modern office having a meeting.

Business Development

At Lōkahi Therapeutics, partnership is foundational to our mission. We collaborate with innovators to accelerate high-potential science and deliver transformative therapies to patients worldwide. Whether you are seeking a development partner for your asset or exploring opportunities to advance Apitox into new indications and markets, Lōkahi provides the expertise, infrastructure, and agility to move programs forward with purpose.

Partnership Pathways

Lōkahi offers two primary collaboration models designed to create meaningful, long-term value:

strategic icon

In-Licensing & Strategic
Collaborations

shaking hands in agreement icon

Out-Licensing & Partnerships
for Apitox

These pathways enable flexibility, alignment, and shared success.

Businesswoman giving a presentation in a modern office, with three colleagues seated at a table, a large window with a city view in the background.

In-Licensing & Collaboration

Lōkahi is therapeutic-area agnostic for later-stage opportunities (Phase 2 and beyond) supported by strong science, clean safety profiles, and actionable clinical data.

We actively pursue differentiated assets and platform technologies where Lōkahi’s development engine can accelerate progress and expand impact.

Ideal opportunities include:

  • Phase 1 clinical data demonstrating clear biologic activity with an acceptable safety profile

  • Late-stage candidates that can advance rapidly through our established development network

  • Assets that benefit from integrated clinical, regulatory, and CMC capabilities

Partners gain direct access to Lōkahi’s scientific leadership, streamlined evaluation processes, and pragmatic, incentive-aligned deal structures designed to advance therapies efficiently and responsibly.

Business professionals in a meeting room listening to a man in a suit giving a presentation, with documents and glasses of water on the table.

Out-Licensing & Partnerships (Apitox)

Apitox, Lōkahi’s lead asset, is a purified bee-venom biologic currently in Phase 3 clinical development for osteoarthritis knee pain.

Lōkahi is now seeking strategic partners to co-develop, out-license, or regionalize Apitox across new markets and therapeutic areas where its multi-component biology may provide meaningful therapeutic advantage.

We welcome regional licensing agreements, co-development structures, and indication-specific collaborations that expand Apitox’s reach and unlock its full clinical and commercial potential.

Submit Your Partnership Proposal

Complete the form below to engage with Lōkahi’s Business Development team.

We review every submission within 5 business days and respond with next steps.

Contact & Follow-Up

The information on this page is provided for general informational purposes and does not constitute an offer to sell or license securities or assets. Any potential partnership will be subject to detailed agreements, legal review, and regulatory approvals.